The benign prostatic hyperplasic devices market in Europe is expected to grow from US$ 648.39 million in 2022 to US$ 994.84 million by 2028; it is estimated to grow at a CAGR of 7.4% from 2022 to 2028.
Players operating in the benign prostatic hyperplasic devices industry focus on investing high amounts in the development of advanced surgical technologies as alternatives to conventional techniques. Advanced devices enabled with new technologies help provide immediate relief and reduce morbidity. In January 2022, ProVerum, an Irish start-up supported by EIT Health, received US$ 31.22 million in Series A funding from Gilde Healthcare, Lightstone Ventures, and Atlantic Bridge. ProVerum has developed ProVee, a cutting-edge treatment solution for men with symptomatic BPH, and it aims to market its innovative device in Europe with the help of recent funding. Further, in June 2021, Zenflow, Inc., a medical device company developing a minimally invasive treatment for urinary obstruction caused by BPH or enlarged prostate, declared the completion of its Series B funding round with a total of US$ 24 million. The investment was led by Invus Opportunities and included participation from Medical Technology Venture Partners, F-Prime Capital, CloudStone Capital, Astia Angels, Golden Seeds, SV Tech Ventures, etc. In June 2021, Procept Biorobotics raised US$ 85 million to commercialize the AquaBeam system as a global BPH treatment. With this product, the company intends to make an impact with its water-based robotic technology in the field of prostate surgery. The series G financing was led by Fidelity Management & Research Company, with additional backing from T. Rowe Price Associates, CPMG, Perceptive Advisors, Viking Global Investors, and Duquesne Family Office. The rise in such investments, funds, and grants for research in the field of BPH treatments is bolstering the benign prostatic hyperplasic devices market growth.
Europe Benign Prostatic Hyperplasic Devices Market Segmentation
The Europe benign prostatic hyperplasic devices market is segmented on the basis of product, procedure type, end user, and country. Based on product, the market is segmented into resectoscopes, urology lasers, radiofrequency ablation devices, prostatic stents, and implants. The resectoscopes segment is expected to hold the largest share of the market in 2022. On the other hand, the urology lasers segment is expected to register the highest CAGR during the forecast period. Based on procedure type, the Europe benign prostatic hyperplasic devices market is segmented into transurethral microwave therapy, transurethral resection of the prostate, transurethral needle ablation of the prostate, laser surgery, urolift surgery, and others. The transurethral resection of the prostate segment held the largest market share in 2022, and it is also expected to register the highest CAGR in the market during the forecast period. Based on end user, the Europe benign prostatic hyperplasic devices market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospital segment held the largest market share in 2022, while the clinics segment is expected to register the highest CAGR during the forecast period. Based on country, the Europe benign prostatic hyperplasic devices market is segmented into U.K., Germany, France, Italy, Spain, and Rest of Europe. In 2022, Germany held a larger market share. On the other side, and it is also expected to register a higher CAGR during the forecast period.
KARL STORZ SE & Co. KG; Olympus Corporation; Boston Scientific Corporation; Teleflex Incorporated; and Richard Wolf GmbH are among the leading companies in the Europe benign prostatic hyperplasic devices market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 648.39 Million |
| Market Size by 2028 | US$ 994.84 Million |
| CAGR (2022 - 2028) | 7.4% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Product
|
| Regions and Countries Covered |
Europe
|
| Market leaders and key company profiles |
|
The Europe Benign Prostatic Hyperplasic Devices Market is valued at US$ 648.39 Million in 2022, it is projected to reach US$ 994.84 Million by 2028.
As per our report Europe Benign Prostatic Hyperplasic Devices Market, the market size is valued at US$ 648.39 Million in 2022, projecting it to reach US$ 994.84 Million by 2028. This translates to a CAGR of approximately 7.4% during the forecast period.
The Europe Benign Prostatic Hyperplasic Devices Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Benign Prostatic Hyperplasic Devices Market report:
The Europe Benign Prostatic Hyperplasic Devices Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Europe Benign Prostatic Hyperplasic Devices Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Europe Benign Prostatic Hyperplasic Devices Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Europe Benign Prostatic Hyperplasic Devices Market
